Related references
Note: Only part of the references are listed.Risk Factors for Acquisition and Clearance of Oral Human Papillomavirus Infection Among HIV-Infected and HIV-Uninfected Adults
Daniel C. Beachler et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2015)
Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial
Allan Hildesheim et al.
VACCINE (2014)
Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical Cancer
Mark Schiffman et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2013)
Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers
Anil K. Chaturvedi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Annual Report to the Nation on the Status of Cancer, 19752009, Featuring the Burden and Trends in Human Papillomavirus (HPV)Associated Cancers and HPV Vaccination Coverage Levels
Ahmedin Jemal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study
Aimee R. Kreimer et al.
LANCET (2013)
Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica
Rolando Herrero et al.
PLOS ONE (2013)
Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naive Women in HPV Vaccine Trials
Mahboobeh Safaeian et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
A. Szarewski et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3
Ana Cecilia Rodriguez et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Prevalence of Oral HPV Infection in the United States, 2009-2010
Maura L. Gillison et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Prevalence of and Risk Factors for Anal Human Papillomavirus Infection Among Young Healthy Women in Costa Rica
Felipe A. Castro et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen et al.
LANCET ONCOLOGY (2012)
Rates and Determinants of Oral Human Papillomavirus Infection in Young Men
Zoe R. Edelstein et al.
SEXUALLY TRANSMITTED DISEASES (2012)
Human Papillomavirus Vaccine Introduction - The First Five Years
Lauri E. Markowitz et al.
VACCINE (2012)
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
X. Castellsague et al.
BRITISH JOURNAL OF CANCER (2011)
Associations between Oral HPV16 Infection and Cytopathology: Evaluation of an Oropharyngeal Pap-Test Equivalent in High-Risk Populations
Carole Fakhry et al.
CANCER PREVENTION RESEARCH (2011)
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Anil K. Chaturvedi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
Aimee R. Kreimer et al.
LANCET ONCOLOGY (2011)
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Joel M. Palefsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
Rolando Herrero et al.
CANCER DISCOVERY (2011)
Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections
Mahboobeh Safaeian et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
Susanne K. Kjaer et al.
CANCER PREVENTION RESEARCH (2009)
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
Francis J. Dessy et al.
HUMAN VACCINES (2008)
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica
Rolando Herrero et al.
VACCINE (2008)
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection - A randomized trial
Allan Hildesheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses
M Ferguson et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR
Leen-Jan van Doorn et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Anal human papillomavirus infection in women and its relationship with cervical infection
BY Hernandez et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus
AR Kreimer et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
Seroprevalence of human papillomavirus-16,-18,-31, and -45 in a population-based cohort of 10 000 women in Costa Rica
SS Wang et al.
BRITISH JOURNAL OF CANCER (2003)
Share Paper
